Correspondence
Research Correspondence
Removal of Contrast Media From the Coronary Sinus Attenuates Renal Injury After Coronary Angiography and Intervention

https://doi.org/10.1016/j.jacc.2010.01.065Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

Please note: Dr. Sievert has received study honoraria, travel expenses, and/or consulting fees from Access Closure, AGA, Angiomed, Ardian, Arstasis, Avinger, Bridgepoint, CardioKinetix, CardioMEMS, Coherex, CSI, EndoCross, EndoTex, Epitek, Evalve, ev3, FlowCardia, Gore, Guidant, Lumen Biochemical, Kensey Nash, Kyoto Medical, Lutonix, Medinol, Medtronic, NCD, NMT, OAS, Occlutech, Osprey, Ovalis, Pathway, PendraCare, Percardia, pfm, Remon, Rox Medical, Sadra, Sorin, Spectranetics, SquareOne, Viacor, and Velocimed; and has stock options in Cardiokinetix, Access Closure, Velocimed, CoAptus, Lumen Biomedical, and Coherex. Dr. Pertile is an employee and stockholder of Osprey Medical. Dr. Kaye is a founder and stockholder of Osprey Medical.